XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
EPS Calculation (Tables)
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of reconciliation of the earnings and shares used in calculating basic and diluted EPS
The following table presents a reconciliation of the earnings/(loss) and shares used in calculating basic and diluted earnings/(loss) per share for the three and nine months ended September 30, 2020 and 2019:
 
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In Thousands, Except Per Share Amounts)2020201920202019
Basic Earnings/(Loss) per Share:
Net income/(loss) to common stockholders$87,210 $95,599 $(725,207)$277,496 
Dividends declared on preferred stock(8,219)(3,750)(21,578)(11,250)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities(325)(280)(91)(808)
Net income/(loss) to common stockholders - basic$78,666 $91,569 $(746,876)$265,438 
Basic weighted average common shares outstanding453,323 451,020 453,170 450,641 
Basic Earnings/(Loss) per Share$0.17 $0.20 $(1.65)$0.59 
Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic$78,666 $91,569 (746,876)265,438 
Interest expense on Convertible Senior Notes 3,898 3,879 — 5,085 
Net income/(loss) to common stockholders - diluted$82,564 $95,448 $(746,876)$270,523 
Basic weighted average common shares outstanding453,323 451,020 453,170 450,641 
Effect of assumed conversion of Convertible Senior Notes to common shares28,920 28,920 — 12,712 
Effect of incremental shares issued on assumed conversion of Warrants11,297 — — — 
Diluted weighted average common shares outstanding (1)
493,540 479,940 453,170 463,353 
Diluted Earnings/(Loss) per Share$0.17 $0.20 $(1.65)$0.58 
(1)At September 30, 2020, the Company had approximately 39.0 million equity instruments outstanding that were not included in the calculation of diluted EPS for the nine months ended September 30, 2020, as their inclusion would have been anti-dilutive.  These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $6.29 and approximately 37.0 million warrants with a weighted average exercise price of $1.87 per share. These equity instruments may have a dilutive impact on future EPS.